JCLA:使用自动浊度免疫分析法定量测定人C1酯酶抑制剂蛋白

2019-05-16 不详 网络

C1抑制剂(C1‐INH)水平或功能受损可导致血管水肿,其原因可能是缓激肽增加。因为治疗方案不同,因此要区分与C1‐INH缺乏相关的血管性水肿和由其他机制引起的血管性水肿非常重要。在遗传性(HAE)和获得性(AAE)血管性水肿中,测量C1‐INH浓度以帮助诊断患者。在此,研究人员描述了一种自动浊度测定法,用于在Optilite®分析仪上测量C1‐INH浓度。

C1抑制剂(C1INH)水平或功能受损可导致血管水肿,其原因可能是缓激肽增加。因为治疗方案不同,因此要区分与C1INH缺乏相关的血管性水肿和由其他机制引起的血管性水肿非常重要。在遗传性(HAE)和获得性(AAE)血管性水肿中,测量C1INH浓度以帮助诊断患者。在此,研究人员描述了一种自动浊度测定法,用于在Optilite®分析仪上测量C1INH浓度。

C1INH浓度范围内建立线性度、精度和干扰。第95百分位参考区间来自120名健康的成人捐赠者。为了比较Optilite C1INH检测与临床实验室的检测方法,两者同时使用了C1INH调查的样本。

Optilite C1INH检测在标准样品稀释的测量范围内呈线性。实验内和实验间的变异性均小于6%。本试验的第95百分位成人参考区间为0.210.38 g/LOptilite浓度与谓词法产生的浓度有较强的相关性(R2 = 0.94, P < 0.0001, slope y = 0.83x)。所有IHAE (n = 24)AAE (n = 3)检测的患者在两种检测方法中浓度均低于测量范围,而所有未诊断HAEAAE的未指定血管性水肿(UAE)患者的浓度均在参考范围内。

研究表明,Optilite方法可以自动精确地定量患者样本中的C1INH浓度。因此,它可以作为一种工具,以帮助调查血管性水肿患者。

原始出处:

Clare E. Tange,  Amrit Kaur ,Quantification of human C1 esterase inhibitor protein using an automated turbidimetric immunoassay

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851991, encodeId=99ec1851991db, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jun 28 02:12:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662292, encodeId=bad016622925b, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Sep 11 05:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928161, encodeId=c169192816122, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Jan 21 16:12:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
    2019-06-28 jklm09
  2. [GetPortalCommentsPageByObjectIdResponse(id=1851991, encodeId=99ec1851991db, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jun 28 02:12:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662292, encodeId=bad016622925b, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Sep 11 05:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928161, encodeId=c169192816122, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Jan 21 16:12:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1851991, encodeId=99ec1851991db, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jun 28 02:12:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662292, encodeId=bad016622925b, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Sep 11 05:12:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928161, encodeId=c169192816122, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Jan 21 16:12:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]